ValiRx granted patent in Australia for VAL201 targeting cancer
ValiRx has been granted a patent for its lead therapeutic compound VAL201 for the treatment of breast, prostate, breast and ovarian cancer in Australia.
ValiRx has been granted a patent for its lead therapeutic compound VAL201 for the treatment of breast, prostate, breast and ovarian cancer in Australia.
The cancer diagnostics company said VAL201 has shown efficacy in prostate, breast and ovarian cancer as well as addressing endometriosis or hormone induced abnormal cell growth in women.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The original patent and technology covering VAL201 is licensed by ValiRx from Cancer Research Technology for use in androgen resistant cancer.
ValiRx has all rights to perform pre-clinical and clinical developments and obtaining regulatory approvals in all territories
"The granting of this latest patent means that ValiRx is able to add to the Company's intellectual property assets and extend its already extensive IP protection for this compound and its intended indications," said Chief Executive Satu Vainikka.
Shares rose 5.26% to 0.50p at 10:13 Thursday.
RD
-
Lifetime ISA reform: Retirement option could be scrapped in overhaulA consultation on a product replacing the Lifetime ISA is set to be launched this year, and the option to use it to save for retirement is expected to be axed in the shake-up
-
HMRC stamp duty crackdown sees probes of property deals jump 88% – what to watch out forFrom bogus stamp duty refund claims to misleading the taxman about who owns a property, HMRC is increasing its scrutiny of stamp duty land tax reporting. Here’s how.
